1. Home
  2. OOMA vs AKBA Comparison

OOMA vs AKBA Comparison

Compare OOMA & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ooma Inc.

OOMA

Ooma Inc.

HOLD

Current Price

$14.41

Market Cap

408.2M

Sector

Technology

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.43

Market Cap

380.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OOMA
AKBA
Founded
2003
2007
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
408.2M
380.4M
IPO Year
2015
2014

Fundamental Metrics

Financial Performance
Metric
OOMA
AKBA
Price
$14.41
$1.43
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$18.77
$5.25
AVG Volume (30 Days)
232.2K
2.3M
Earning Date
05-27-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
188.46
93.94
EPS
0.23
N/A
Revenue
$114,490,000.00
N/A
Revenue This Year
$20.35
N/A
Revenue Next Year
$3.82
N/A
P/E Ratio
$63.65
N/A
Revenue Growth
9.53
N/A
52 Week Low
$9.79
$1.14
52 Week High
$15.15
$4.08

Technical Indicators

Market Signals
Indicator
OOMA
AKBA
Relative Strength Index (RSI) 58.68 54.02
Support Level $10.95 $1.30
Resistance Level $14.83 $1.55
Average True Range (ATR) 0.50 0.06
MACD -0.04 -0.00
Stochastic Oscillator 56.32 67.65

Price Performance

Historical Comparison
OOMA
AKBA

About OOMA Ooma Inc.

Ooma Inc is a communications services company. It is a smart software-as-a-service (SaaS) and unified communications platform that deliver voice and collaboration features including messaging, intelligent virtual attendants and video conferencing, and residential phone service provides PureVoice high-definition voice quality, advanced functionality and integration with mobile devices. Its services rely upon the following main elements: multi-tenant cloud service, on-premise devices, desktop and mobile applications, and calling platforms. It generates revenues from the sale of subscriptions and other services.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Share on Social Networks: